Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Amgen Europe B.V., Minervum 7061, NL-4817 ZK Breda, The Netherlands
Kyprolis 10 mg powder for solution for infusion.
Kyprolis 30 mg powder for solution for infusion.
Kyprolis 60 mg powder for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for solution for infusion. White to off-white lyophilised powder. |
Kyprolis 10 mg powder for solution for infusion: Each vial contains 10 mg of carfilzomib.
Kyprolis 30 mg powder for solution for infusion: Each vial contains 30 mg of carfilzomib.
Kyprolis 60 mg powder for solution for infusion: Each vial contains 60 mg of carfilzomib.
After reconstitution, 1 mL of solution contains 2 mg of carfilzomib.
Excipient with known effect: Each mL of reconstituted solution contains 7 mg of sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that selectively and irreversibly binds to the N-terminal threonine containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome, and displays little to no activity against other protease classes. Carfilzomib had antiproliferative and proapoptotic activities in preclinical models in haematologic tumours. |
| List of Excipients |
|---|
|
Betadex sulfobutyl ether sodium |
Kyprolis 10 mg powder for solution for infusion: 10 mL type I clear glass vial, closed with fluoropolymer laminated elastomeric stopper and aluminium seal with a light blue plastic flip off cap.
Kyprolis 30 mg powder for solution for infusion: 30 mL type I clear glass vial, closed with fluoropolymer laminated elastomeric stopper and aluminium seal with an orange plastic flip off cap.
Kyprolis 60 mg powder for solution for infusion: 50 mL type I clear glass vial, closed with fluoropolymer laminated elastomeric stopper and aluminium seal with a purple plastic flip off cap.
Pack size of one vial.
Amgen Europe B.V., Minervum 7061, NL-4817 ZK Breda, The Netherlands
EU/1/15/1060/002
EU/1/15/1060/003
EU/1/15/1060/001
Date of first authorisation: 19 November 2015
| Drug | Countries | |
|---|---|---|
| KYPROLIS | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.